Current status and prospect of particle therapy for esophageal cancer

Abstract

Esophageal cancer is among the top causes of cancer-related mortality worldwide, and the main treatment modality for locally advanced esophageal cancer is concurrent chemoradiotherapy. The current photon-based radiotherapy modalities and procedures have increased the incidence of treatment-related cardiac and pulmonary complications. Additionally, anatomical changes in the esophagus resulting from diaphragmatic movement, weight loss, and tumor progression present challenges for radiotherapy. These challenges have spurred interest in particle therapies, such as proton beam therapy (PBT) and heavy-ion therapy, for esophageal cancer. This paper comprehensively reviews the dosimetric advantages, clinical efficacy, and limitations of PBT and heavy-ion therapy for esophageal cancer and discusses their prospects. This highlights the unique dosimetric benefits of these therapies, particularly their ability to deliver high-dose radiation precisely to the tumor while sparing the surrounding normal organs and tissues. Although PBT and heavy-ion therapy demonstrate superior clinical efficacy compared to photon therapy, they are not without limitations. Multiple studies are needed to further validate and supplement the existing clinical and preclinical data to better exploit the benefits of PBT and thereby provide improved survival advantages to these patients

Keywords

Esophageal cancer / proton therapy / carbon-ion therapy / radiotherapy

References

[1] SungH, FerlayJ, SiegelRL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249.

[2] AllemaniC, Matsuda T, Di CarloV, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.

[3] McCormackVA, MenyaD, MunishiMO, et al. Informing etiologic research priorities for squamous cell esophageal cancer in Africa: A review of setting-specific exposures to known and putative risk factors. Int J Cancer. 2017;140(2):259–271.

[4] ShapiroJ, van Lanschot JJB, HulshofM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–1098.

[5] AjaniJA, D'Amico TA, BentremDJ, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(4):393–422.

[6] BedenneL, MichelP, BouchéO, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–1168.

[7] LaRiviereMJ, SantosPMG, Hill-KayserCE, et al. Proton Therapy. Hematol Oncol Clin North Am. 2019;33(6):989–1009.

[8] SolidumJGN, RojoRD, WoJY, et al. Proton Beam Therapy for Esophageal Cancer. Cancers (Basel). 2022;14(16).

[9] VošmikM, HodekM, BukaD, et al. Cardiotoxicity of radiation therapy in esophageal cancer. Rep Pract Oncol Radiother. 2020;25(3):318–322.

[10] WilsonRR. Radiological use of fast protons. Radiology. 1946;47(5):487–491.

[11] RucińskiA, Bauer J, CampbellP, et al. Preclinical investigations towards the first spacer gel application in prostate cancer treatment during particle therapy at HIT. Radiat Oncol. 2013;8:134.

[12] MoignierA, Gelover E, WangD, et al. Theoretical Benefits of Dynamic Collimation in Pencil Beam Scanning Proton Therapy for Brain Tumors: Dosimetric and Radiobiological Metrics. Int J Radiat Oncol Biol Phys. 2016;95(1):171-180.

[13] ParzenJS, ChuongMD, ChangJ, et al. Dosimetry and Acute Toxicity Profile of Patients With Esophageal Cancer Treated With Proton Beam Radiation Therapy: Outcomes From the Proton Collaborative Group REG001-09 Trial. Adv Radiat Oncol. 2021;6(5):100751.

[14] XiM, XuC, LiaoZ, et al. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017;99(3):667–676.

[15] OonsiriS, Kitpanit S, KannarunimitD, et al. Comparison of intensity modulated proton therapy beam configurations for treating thoracic esophageal cancer. Phys Imaging Radiat Oncol. 2022;22:51–56.

[16] HiranoY, Onozawa M, HojoH, et al. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol. 2018;13(1):23.

[17] ZhangY, Jabbour SK, ZhangA, et al. Proton beam therapy can achieve lower vertebral bone marrow dose than photon beam therapy during chemoradiation therapy of esophageal cancer. Med Dosim. 2021;46(3):229–235.

[18] BhangooRS, DeWeesTA, YuNY, et al. Acute Toxicities and Short-Term Patient Outcomes After Intensity-Modulated Proton Beam Radiation Therapy or Intensity-Modulated Photon Radiation Therapy for Esophageal Carcinoma: A Mayo Clinic Experience. Adv Radiat Oncol. 2020;5(5):871–879.

[19] LinSH, Merrell KW, ShenJ, et al. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiother Oncol. 2017;123(3):376–381.

[20] OnoT, WadaH, IshikawaH, Tamamura H, TokumaruS. Clinical Results of Proton Beam Therapy for Esophageal Cancer: Multicenter Retrospective Study in Japan. Cancers (Basel). 2019;11(7):993.

[21] OnoT, WadaH, IshikawaH, et al. Proton beam therapy is a safe and effective treatment in elderly patients with esophageal squamous cell carcinoma. Thorac Cancer. 2020;11(8):2170–2177.

[22] LinSH, HobbsBP, VermaV, et al. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020;38(14):1569-1579.

[23] LinSH, KomakiR, LiaoZ, et al. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;83(3):e345-351.

[24] JethwaKR, Haddock MG, TryggestadEJ, et al. The emerging role of proton therapy for esophagus cancer. J Gastrointest Oncol. 2020;11(1):144–156.

[25] LiY, KardarL, LiX, et al. On the interplay effects with proton scanning beams in stage III lung cancer. Med Phys. 2014;41(2):021721.

[26] YuJ, ZhangX, LiaoL, et al. Motion-robust intensity-modulated proton therapy for distal esophageal cancer. Med Phys. 2016;43(3):1111–1118.

[27] ChangJY, ZhangX, KnopfA, et al. Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee. Int J Radiat Oncol Biol Phys. 2017;99(1):41–50.

[28] LewisGF, GattoRG, PorgesSW. A novel method for extracting respiration rate and relative tidal volume from infrared thermography. Psychophysiology. 2011;48(7):877–887.

[29] KarubeM, Nakayama H. Proton therapy for patients with esophageal cancer: History, characteristics, clinical outcome and future direction of proton beam therapy. Glob Health Med. 2021;3(3):149–156.

[30] HughesJR, Parsons JL. FLASH Radiotherapy: Current Knowledge and Future Insights Using Proton-Beam Therapy. Int J Mol Sci. 2020;21(18):6492.

[31] ShaoW, TangX, BaiY, et al. Modulation of lateral positions of Bragg peaks via magnetic fields inside cancer patients: Toward magnetic field modulated proton therapy. Med Phys. 2017;44(10):5325–5338.

[32] KarschL, Beyreuther E, EnghardtW, et al. Towards ion beam therapy based on laser plasma accelerators. Acta Oncol. 2017;56(11):1359–1366.

[33] HoffmannA, ObornB, MoteabbedM, et al. MR-guided proton therapy: a review and a preview. Radiat Oncol. 2020;15(1):129.

[34] JäkelO. Medical physics aspects of particle therapy. Radiat Prot Dosimetry. 2009;137(1-2):156-166.

[35] KamadaT, TsujiiH, BlakelyEA, et al. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncol. 2015;16(2):e93-e100.

[36] PomposA, Durante M, ChoyH. Heavy Ions in Cancer Therapy. JAMA Oncol. 2016;2(12):1539–1540.

[37] LuoH, YangZ, ZhangQ, et al. Carbon Ion Therapy Inhibits Esophageal Squamous Cell Carcinoma Metastasis by Upregulating STAT3 Through the JAK2/STAT3 Signaling Pathway. Front Public Health. 2020;8:579705.

[38] IsozakiY, YasudaS, AkutsuY, et al. Salvage Carbon-ion Radiotherapy for Isolated Lymph Node Recurrence Following Curative Resection of Esophageal Cancer. Anticancer Res. 2018;38(11):6453–6458.

[39] TakakusagiY, Yoshida D, KusanoY, et al. Dosimetric Comparison Between Carbon-ion Radiotherapy and Photon Radiotherapy for Stage I Esophageal Cancer. In Vivo. 2021;35(1):447–452.

[40] HaefnerMF, Sterzing F, KrugD, et al. Intrafractional dose variation and beam configuration in carbon ion radiotherapy for esophageal cancer. Radiat Oncol. 2016;11(1):150.

[41] KanoM, YamadaS, HoshinoI, et al. Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. Anticancer Res. 2009;29(11):4433–4438.

[42] DuJ, Kageyama SI, HirataH, et al. Comparative analysis of the immune responses in cancer cells irradiated with X-ray, proton and carbon-ion beams. Biochem Biophys Res Commun. 2021;585:55–60.

RIGHTS & PERMISSIONS

2024 2024 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.